DYNAMIC INDUSTRIES Q2 FY27 (STANDALONE) ⚠️ WEAK

• Net Profit: ₹0 Cr Flat YoY | ↓51% QoQ

• Revenue: ₹21 Cr ↑19% YoY | ↓1% QoQ

• EBITDA: ₹1 Cr Flat YoY | ↓32% QoQ

• EBITDA Margin: 5.7% vs 6.8% YoY ↓110 bps | 8.3% QoQ ↓260 bps

AVEER FOODS Q2 FY27 (STANDALONE) 🌱 OK

• Net Profit: ₹2 Cr ↓14% YoY | ↑175% QoQ

• Revenue: ₹39 Cr ↑2% YoY | ↑13% QoQ

• EBITDA: ₹3 Cr ↓19% YoY | ↑78% QoQ

• EBITDA Margin: 7.4% vs 9.3% YoY ↓190 bps | 4.7% QoQ ↑270 bps

ENKEI WHEELS Q2 FY27 (STANDALONE) 🌱 OK

• Net Profit: ₹7 Cr ↓8% YoY | ↓29% QoQ

• Revenue: ₹345 Cr ↑30% YoY | ↑8% QoQ

• EBITDA: ₹32 Cr ↑8% YoY | ↓5% QoQ

• EBITDA Margin: 9.4% vs 11.3% YoY ↓190 bps | 10.7% QoQ ↓130 bps

KOKUYO CAMLIN Q2 FY27 (STANDALONE) ⚠️ WEAK

• Net Profit: ₹3 Cr ↓67% YoY | ↓65% QoQ

• Revenue: ₹186 Cr ↑6% YoY | ↓19% QoQ

• EBITDA: ₹9 Cr ↓46% YoY | ↓44% QoQ

• EBITDA Margin: 4.7% vs 9.2% YoY ↓450 bps | 6.8% QoQ ↓210 bps

ORIENTAL AROMATICS Q2 FY27 🏆 EXCELLENT

• Net Profit: ₹6 Cr ↑684% YoY | ↑130% QoQ

• Revenue: ₹318 Cr ↑17% YoY | ↑22% QoQ

• EBITDA: ₹25 Cr ↑47% YoY | ↑28% QoQ

• EBITDA Margin: 7.9% vs 6.4% YoY ↑150 bps | 7.6% QoQ ↑30 bps

APOLLO HOSPITALS Q2 FY27 🌟 GREAT

• Net Profit: ₹660 Cr ↑34% YoY | ↑8% QoQ

• Revenue: ₹7,615 Cr ↑23% YoY | ↑10% QoQ

• EBITDA: ₹1,191 Cr ↑29% YoY | ↑11% QoQ

• EBITDA Margin: 15.6% vs 14.9% YoY ↑70 bps | 15.5% QoQ ↑10 bps

LUMINO: Q2 SL NET PROFIT 530M RUPEES VS 352M (YOY)

LUMINO: Q2 EBITDA 845M RUPEES VS 629M (YOY); Q2 EBITDA MARGIN 12.77% VS 12.37% (YOY)

LUMINO: Q2 REVENUE 6.6B RUPEES VS 5.1B (YOY)

HITECHGEAR: Q2 CONS NET PROFIT 107M RUPEES VS 60.1M (YOY)

HITECHGEAR: Q2 EBITDA 334M RUPEES VS 278M (YOY); Q2 EBITDA MARGIN 12.01% VS 11.82% (YOY)

HITECHGEAR: Q2 REVENUE 2.78B RUPEES VS 2.35B (YOY)

AFCONS: Q2 SL NET PROFIT 1.3B RUPEES VS 1.12B (YOY)

AFCONS: Q2 EBITDA 1.8B RUPEES VS 3.4B (YOY); Q2 EBITDA MARGIN 6.85% VS 11.31% (YOY)

AFCONS: Q2 REVENUE 26.35B RUPEES VS 29.9B (YOY)

KANSAINER: Q2 SL NET PROFIT 1.48B RUPEES VS 1.36B (YOY)

KANSAINER: Q2 EBITDA 2.23B RUPEES VS 2.12B (YOY); Q2 EBITDA MARGIN 9.85% VS 11.32% (YOY)

KANSAINER: Q2 REVENUE 22.68B RUPEES VS 19.07B (YOY)

GRINFRA: Q2 CONS NET PROFIT 2.9B RUPEES VS 1.9B (YOY)

GRINFRA: Q2 EBITDA 4.33B RUPEES VS 3.57B (YOY); Q2 EBITDA MARGIN 18.63% VS 22.29% (YOY)

GRINFRA: Q2 REVENUE 23.3B RUPEES VS 16B (YOY)

U.S. TREASURY SAYS IT IS IMPOSING SANCTIONS AGAINST FOUR INDIA-BASED INDIVIDUALS AND NINE COMPANIES FOR SUPPORTING IRAN’S SHADOW FLEET, AND IS ALSO DESIGNATING TURKEY-BASED FUGO GROUND SERVICES FOR SUPPORTING IRAN’S AVIATION SECTOR

U.S. TREASURY’S OFAC HAS ISSUED A NEW ALERT WARNING INDUSTRY OF THE RISKS OF DEALING WITH POTENTIALLY FALSELY FLAGGED VESSELS, WHICH IT SAYS CARRY NO VALID PROTECTION OR INSURANCE

TRUMP SAYS THE STOCK MARKET JUST HIT ANOTHER RECORD HIGH — “91 DAYS IN JUST A SHORT PERIOD OF TIME, LESS THAN TWO YEARS” — AND THAT “YOUR 401(K)S ARE THROUGH THE ROOF” AND RECORD-SETTING - TRUTH SOCIAL

KIMS Q2 FY27 (CONSOLIDATED) ✅ GOOD

• Net Profit: ₹74.60 Cr ↑3.61% YoY | ↑99.47% QoQ

• Revenue: ₹1,344.40 Cr ↑39.94% YoY | ↑13.98% QoQ

• EBITDA: ₹260.30 Cr ↑27.60% YoY | ↑16.36% QoQ

• EBITDA Margin: 19.36% vs 21.23% YoY ↓187 bps | 18.97% QoQ ↑39 bps

SHUKRA PHARMACEUTICALS Q2FY27

REVENUE 44.00 CR VS 6.00 CR
(+652.00% YOY┃+88.00% QOQ)

EBITDA 19.00 CR VS 0.00 CR
(TURNAROUND YOY┃-2.00% QOQ)

EBITDA MARGIN 42.30% VS -7.10% YOY & 81.40% QOQ

PAT 13.00 CR VS 2.00 CR
(+435.00% YOY┃-2.00% QOQ)

EPS 0.29 VS 0.05
(+480.00% YOY┃-3.33% QOQ)

NRB BEARINGS Q2FY27

REVENUE 386.00 CR VS 325.00 CR
(+18.77% YOY┃+4.32% QOQ)

EBITDA 67.00 CR VS 54.00 CR
(+24.07% YOY)

EBITDA MARGIN 17.30% VS 16.50% YOY

PAT 36.00 CR VS 41.00 CR
(-12.00% YOY┃-4.00% QOQ)

EPS 3.66 VS 4.19
(-12.65% YOY┃+1.67% QOQ)

GALAXY SURFACTANTS Q2FY27

REVENUE 1,810.00 CR VS 1,326.00 CR
(+36.50% YOY┃+1.57% QOQ)

EBITDA 190.00 CR VS 111.00 CR
(+71.17% YOY┃-23.69% QOQ)

EBITDA MARGIN 10.50% VS 8.30% YOY & 14.00% QOQ

PAT 120.00 CR VS 66.00 CR
(+81.82% YOY┃-27.71% QOQ)

EPS 33.78 VS 18.75
(+80.16% YOY┃-27.82% QOQ)

ALL TIME PLASTICS Q2FY27

REVENUE 174.00 CR VS 147.00 CR
(+18.37% YOY┃+7.41% QOQ)

EBITDA 14.00 CR VS 16.00 CR
(-16.00% YOY┃-42.00% QOQ)

EBITDA MARGIN 7.80% VS 11.00% YOY & 14.50% QOQ

PAT 4.00 CR VS 4.00 CR
(-11.00% YOY┃-70.00% QOQ)

EPS 0.55 VS 0.72
(-23.61% YOY┃-69.95% QOQ)

ENTERO HEALTHCARE SOLUTIONS Q2FY27

REVENUE 2,087.00 CR VS 1,571.00 CR
(+32.85% YOY┃+7.58% QOQ)

EBITDA 111.00 CR VS 62.00 CR
(+79.03% YOY┃+14.43% QOQ)

EBITDA MARGIN 5.30% VS 4.00% YOY & 5.00% QOQ

PAT 61.00 CR VS 37.00 CR
(+66.00% YOY┃+17.00% QOQ)

EPS 10.47 VS 7.26
(+44.21% YOY┃+19.38% QOQ)

CUMMINS INDIA Q2FY27

REVENUE 3,301.00 CR VS 3,170.00 CR
(+4.13% YOY┃-3.65% QOQ)

PAT 507.00 CR VS 622.00 CR
(-18.49% YOY┃-16.75% QOQ)

EPS 18.30 VS 22.45
(-18.49% YOY┃-16.74% QOQ)